ArticleBMC nephrology2026
Icariin protects against cisplatin-induced renal injury and ferroptosis via JNK pathway in mice.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) induced by cisplatin (DDP) is a critical complication that elevates patient mortality and worsens clinical outcomes. Recent evidence highlights ferroptosis as a key contributor to AKI pathogenesis. Icariin (ICA), a natural flavonoid glycoside with antioxidant, anti-apoptotic, and anti-ferroptotic properties, holds therapeutic potential. This study aimed to explore ICA’s protective effects against DDP-induced AKI in mice and human renal tubular epithelial (HK-2) cells, focusing on its anti-ferroptotic mechanisms.
methodsA DDP-induced AKI mouse model was established using a single intraperitoneal injection of 30 mg/kg DDP. In vitro, HK-2 cells were treated with DDP to mimic renal injury. ICA’s effects were evaluated through histopathological analysis, measurement of kidney injury markers (e.g., Scr, BUN), and assessment of oxidative stress (ROS, MDA), apoptosis (Bax, cleaved caspase-3), and ferroptosis-related markers (Fe²⁺, ACSL4, GPX4, FTH1). Mitochondrial morphology was examined via electron microscopy. Protein expression and phosphorylation of JNK signaling components were analyzed using Western blot.
resultsIn mice, ICA alleviated DDP-induced tubular dilation, mucus accumulation, and epithelial shedding, and reduced levels of kidney injury markers. It suppressed apoptosis, as indicated by decreased Bax and cleaved caspase-3, reduced oxidative stress, reflected by lower ROS and MDA levels, and inhibited ferroptosis through a reduction in Fe²⁺. In HK-2 cells, ICA counteracted DDP-induced cytotoxicity, restored mitochondrial integrity, and mitigated ferroptosis, evidenced by decreased ACSL4 and increased GPX4 and FTH1. Mechanistically, ICA inhibited JNK phosphorylation in both models. Animal studies further confirmed that the renoprotective effects of ICA were mediated through modulation of the JNK pathway.
conclusionICA alleviates DDP-induced AKI by inhibiting apoptosis, oxidative stress, and ferroptosis, partially through suppression of JNK signaling. These findings underscore ICA’s potential as a therapeutic agent for DDP-associated kidney injury, with ferroptosis and JNK pathways as critical targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.